Cipher Pharmaceuticals Reports First Quarter 2019 Financial Results

Friday, May 10, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

 (IN THOUSANDS OF U.S. DOLLARS) 

Three months endedMarch 31, 2019

Three months endedMarch 31, 2018

$

$

Income (loss) from continuing operations

816

(951)

Add back:

Depreciation and amortization

299

226

Interest expense, net

222

130

Income taxes

423

(141)

EBITDA

1,760

(736)

Change in fair value of derivative financial instrument

(12)

(321)

Loss (gain) from the translation of Canadian cash balances

(26)

41

Impairment of intangible assets

1,832

Share-based compensation

32

156

Adjusted EBITDA

1,754

972



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store